Home › Trials › NCT03390894

Long-term follow-up of early stage breast cancer patients

Long-Term Follow-up Study of Early Stage Breast Cancer Patients Included in GEICAM Studies

Observational Spanish Breast Cancer Research Group · NCT03390894

This study is tracking early-stage breast cancer patients for about 30 years after their treatment to see how well the treatments work and what long-term effects they might have.

Quick facts

Study typeObservational
Enrollment8000 (estimated)
Ages18 Years and up
SexFemale
SponsorSpanish Breast Cancer Research Group Academic / other
Locations73 sites (Pamplona, Navarre and 72 other locations)
Trial IDNCT03390894 on ClinicalTrials.gov

What this trial studies

This multicenter cohort study aims to collect long-term follow-up data from patients diagnosed with early-stage invasive breast cancer who participated in neoadjuvant or adjuvant clinical trials conducted by the GEICAM group. Patients will be monitored for approximately 30 years after completing their original study follow-up. The study seeks to evaluate the long-term efficacy and potential sequelae of treatments, providing valuable insights for healthcare professionals and society. The data collected will enhance understanding of the long-term evolution of early-stage invasive breast cancer.

Who should consider this trial

Good fit: Ideal candidates are patients who have previously participated in neoadjuvant or adjuvant clinical trials with GEICAM.

Not a fit: Patients who were excluded from the original studies due to non-compliance or withdrawal of consent may not benefit from this study.

Why it matters

Potential benefit: If successful, this study could provide critical insights into the long-term outcomes and treatment effects for early-stage breast cancer patients.

How similar studies have performed: Other studies have shown success in long-term follow-up of cancer patients, indicating that this approach is valuable and has been previously tested.

Eligibility criteria

Show full inclusion / exclusion criteria 
Inclusion Criteria:

* Patients included in neoadjuvant and adjuvant clinical trials with GEICAM's participation. If any of these patients had taken part or is participating in another clinical trial, she/he is eligible for this trial and her/his information will also be collected.
* Patients whose death or contact loss has not been previously collected in the databases of the original studies.

Exclusion Criteria:

* Patient who were not included in the analyses of the original studies due to non-compliance of the eligibility criteria or the original study informed consent withdrawal.

Where this trial is running

Pamplona, Navarre and 72 other locations

+23 more sites — see ClinicalTrials.gov for the full list.

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
View on ClinicalTrials.gov → Find more trials like this →
Conditions Invasive Breast Cancer Early StagesLong-term Follow-UpPrevious Neoadjuvant treatmentPrevious Adjuvant treatment
Last reviewed 2026-06-10 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.